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Edited by Hans-Dieter KlenkAbstract The inﬂuenza A virus PB1-F2 protein predominantly
localizes in the mitochondria of virus-infected cells. A series of
cDNAs encoding N- and C-terminal deletion mutants and site-di-
rected mutagenesis of the basic residues of PB1-F2 appended to
3xFLAG revealed the domain from residues 46 to 75 to be both
necessary and suﬃcient for mitochondrial targeting. In addition,
the subdomain residues 63–75 and both Lys73 and Arg75 are
minimally required for mitochondrial localization. Transfection
of untagged- and 3xFLAG tagged-PB1-F2 into Vero, HeLa
and MDCK cells changed the mitochondrial morphology from
a ﬁlamentous to a dotted structure and suppressed the inner-
membrane potential.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Inﬂuenza A virus (IAV) is one of the most common infec-
tious pathogens in both humans and animals, and causes con-
siderable morbidity and mortality [1]. The pathogenicity of
IAV is complex, being inﬂuenced by each of the eight RNA
gene segments that are known to encode the viral 10 proteins
with an additional small protein recently found and termed
PB1-F2, the open reading frame of which overlaps the PB1
open reading frame [2,3]. Viral RNA replication is carried
out through the concerted action of three polymerase subunits
(PA, PB1 and PB2) and nucleoprotein and the resulting nucle-
ocapsids are exported from the nucleus via the proteins M1
and NS2 [4–10].
Besides the role of these viral proteins in viral proliferation,
it has been reported that many viral factors induce cell injury
and apoptosis of the infected cells. Viral proteins PB2 and M
inhibit mitochondrial b-oxidation [11,12] and PB1-F2 predom-
inantly suppresses the mitochondrial inner-membrane poten-
tial [2,3]. In the process of inﬂuenza virus replication, virus
generates double-stranded RNA (dsRNA) and dsRNA-acti-
vated protein kinase (PKR). The activated PKR induces both
Fas and Fas-ligand, which in turn induce caspases, a family of
cysteine proteases structurally related to interleukin-1-b-con-
verting enzyme, which are related to apoptosis [13–16]. In
addition, other viral proteins, such as neuraminidase and hem-*Corresponding author. Fax: +81 88 633 7425.
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transforming growth factor-b [17] or alteration of the intracel-
lular redox conditions [18]. Conﬂicting results of inﬂuenza
virus NS1 protein as an inducer of apoptosis [19] and an anti-
apoptotic regulator [20] have been reported.
In the present study, we analyzed the molecular mechanisms
of mitochondrial targeting and the functions of a new member
of the inﬂuenza virus proteins, PB1-F2. To analyze intracellu-
lar localization of PB1-F2, we initially made a chimeric protein
consisting of 10.5 kDa of PB1-F2 genetically fused to 29 kDa
of enhanced green ﬂuorescent protein (EGFP) as reported [3].
However, we were able to detect only a small percentage (less
than 15–20%) of mitochondrial localization of chimeric PB1-
F2 in the PB1-F2-positive HeLa and Vero cells, and most of
the chimeric protein was found in the cytosol, with the percent-
age value of mitochondrial localization being signiﬁcantly
lower than that in MDBK cells infected with the inﬂuenza
virus PR8 [3]. The diﬀerence may be due to a steric hindrance
of the chimeric PB1-F2 protein by linkage with the relatively
large acidic reporter protein EGFP. We made a chimeric
PB1-F2 fused to a small reporter protein, 3xFLAG, with a
molecular mass of 2.9 kDa instead of the large EGFP. Under
these conditions, we found that most of the chimeric protein
eﬃciently (about 70–80%) localizes in mitochondria and the
predicted mitochondrial targeting sequence (MTS) was diﬀer-
ent from those previously reported by analysis of the chimeric
PB1-F2-EGFP [3], although the C-terminal region of the
newly identiﬁed MTS overlaps the N-terminal region of the re-
ported MTS. We report here the PB1-F2 domain necessary
and suﬃcient for mitochondrial localization, and also demon-
strate that full-length PB1-F2 as well as deletion mutants local-
izing in mitochondria show a loss of mitochondrial potential
and mitochondrial rounding.2. Materials and methods
2.1. Cells and a virus
Vero and MDCK cells in Eagles minimum essential medium and
HeLa cells in Dulbeccos minimum essential medium, supplemented
with 10% fetal calf serum, were grown as monolayers. Inﬂuenza virus
A/Puerto Rico/8/34 (H1N1) (PR8) (Mt. Sinai strain) was used in this
study. The virus was propagated and titrated in MDCK cells. Vero,
HeLa and MDCK cells were infected at a m.o.i. of 5 plaque forming
units per cell.
2.2. Construction of expression plasmids
The PB1-F2 coding sequence was ampliﬁed by PCR from the plas-
mid pBMSA-PB1 coding inﬂuenza A virus PR8 PB1 (purchased from
Riken). PB1-F2 was cloned in the pEGFP-N1 expressing vector
(Clontech) using the upstream (5 0) primer CTTCTCGAGATGG-ation of European Biochemical Societies.
332 H.Yamada et al. / FEBS Letters 578 (2004) 331–336GACAGGAACAGGATACAC containing an initiation codon and
XhoI site, and the downstream (3 0) primer AGCGAATTCAC-
TCGTGTTTGCTGAACAACCT containing a stop codon and EcoRI
site. For cloning of PB1-F2 with 3xFLAG tag in the p3xFLAG-
myc-CMV-26 expressing vector (Sigma), we used the 5 0 primer
containing an initiation codon and HindIII site, and the 3 0 primer con-
taining a stop codon and EcoRI site. For cloning of PB1-F2 with
EGFP in the pEGFP-C3 expressing vectors (Clontech), we used the
5 0 primer containing an initiation codon and XhoI site, and the 3 0 pri-
mer containing a stop codon and EcoRI site. The nomenclature of the
N- and C-terminal deletion mutants indicates the deleted amino acids;
for example, 3xFLAG-31/75 indicates a truncated PB1-F2 protein con-
taining amino acids 31–75 N-terminally fused to the 3xFLAG tag. All
N- and C-terminal deletion mutants were made by using 5 0 primers
containing introduced initiation codons and by using 3 0 primers con-
taining introduced termination codons, respectively. The point mu-
tants were made by substituting Lys and Arg residues with Ala. The
nomenclature of the point mutants indicates the substituted amino
acids; for example, 3xFLAG-K73A/R75A indicates a mutated PB1-
F2 protein containing a Lys73-to-Ala and an Arg75-to-Ala mutation.
All point mutants were made by using the 3 0 primers with the desired
mutations; for example, 3xFLAG-K73A/R75A was made with the 3 0
primer GTCGAATTCTACTCGTGTTTGCTGAACAACCTCCA-
TCGTTTCAATACAGCAGTTGCCAAAAATAC. The correctness
of the plasmid constructs was analyzed by DNA sequencing. The
expression of the size of plasmid constructs was conﬁrmed by Western
blotting.2.3. Preparation of PB1-F2 antibodies
For cloning of PB1-F2 in the Escherichia coli (E. coli) expression
vector pET-21a (Novagen), we used the 5 0 primer containing an initi-
ation codon and EcoRI site, and the 3 0 primer containing XhoI site
without a stop codon. PB1-F2-6xHis fusion protein was puriﬁed using
HiTrap Chelating HP (Amersham BioSciences). Puriﬁed 1 mg PB1-F2-
6xHis fusion protein in 1 ml saline was emulsiﬁed with an equal vol-
ume of complete Freunds adjuvant for the primary injection and with
the incomplete form for booster injection, and injected into a Japan
white rabbit several times at 3-week intervals. Antiserum with a satis-
factory titer was applied to an aﬃnity column of immunogen-coupled
epoxy-activated Sepharose 6B and antigen-speciﬁc antibodies were ob-
tained by elution with 0.2 M glycine/HCl buﬀer, pH 2.8.Fig. 1. Intracellular localization of untagged and tagged PB1-F2
fusion constructs. Vero cells transfected with plasmids expressing PB1-2.4. Transfection and immunoﬂuorescence detection
Vero, HeLa and MDCK cells were transfected by using FuGENE 6
transfection reagent (Roche) according to the manufacturers instruc-
tions. The indirect immunoﬂuorescence assay was performed as de-
scribed previously [21,22]. Mouse monoclonal and rabbit polyclonal
antibodies against the FLAG tag (Sigma) and rabbit polyclonal anti-
bodies against PB1-F2 were used for immunoﬂuorescence detection.
Mouse monoclonal antibodies against the native form of cytochrome
c were purchased from PharMingen. Rabbit anti-inﬂuenza A, B anti-
bodies were purchased from Takara. Annexin V with Alexa Fluor
594 conjugate (Molecular Probes) was used according to the manufac-
turers instructions. Mitochondrial transmembrane potential was mon-
itored using MitoTracker Red CMXRos (Molecular Probes),
tetramethylrhodamine ethyl ester (TMRE) (Molecular Probes) and
Rhodamine 123 (Molecular Probes). pDSRed2-Mito was from
Clontech. Fluorescent images were viewed and recorded with Zeiss
Axioplan 2 microscopes. For each plasmid construction, over 500
PB1-F2-expressing cells in at least 15 randomly selected high power
ﬁelds (400·) were counted to calculate percentage of the cells with
PB1-F2 within mitochondria.F2 (A–C), 3xFLAG-PB1-F2-1/87 (D–F), EGFP-PB1-F2-1/87 (G–I),
3xFLAG-46/75 (J–L), 3xFLAG-63/75 (M–O), EGFP-PB1-F2-63/75
(P–R), 3xFLAG-PB1-F2-78K/79R/81R (S–U) and 3xFLAG-PB1-F2-
73K/75R (V–X) were incubated with MitoTracker Red and were ﬁxed
24 h after transfection and labeled with mouse anti-FLAG monoclonal
antibodies and FITC-conjugated anti-mouse antibodies.3. Results
3.1. Eﬃcient mitochondrial targeting of 3xFLAG-PB1-F2
The subcellular localization of PB1-F2 in Vero cells at 24 h
after transfection was analyzed by immunoﬂuorescence assay.
PB1-F2 localization in the mitochondria was found in 73 ± 4%
of the PB1-F2-positive cells, as identiﬁed by the colocalization
with MitoTracker Red dye (Fig. 1A–C). In the rest of the PB1-F2-positive cells, it was distributed in the cytoplasm and nu-
cleus (data not shown). Subcellular localization of PB1-F2
with 3xFLAG tag in mitochondria was also found in
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tion of PB1-F2 with EGFP was found only in 14 ± 1.5% of
EGFP-PB1-F2-positive cells (Fig. 1G–I). In addition, as re-
ported also for PR8-infected cells, certain cells expressing
mitochondrial 3xFLAG-PB1-F2 exhibited a loss of mitochon-
drial membrane potential, as indicated by decreased staining
with MitoTracker Red and alteration of the mitochondrial
morphology from tubular to rounded and vesicular forms
(Fig. 3A–I) [2,3]. These results suggest that a chimeric PB1-
F2 fused to a small 3xFLAG instead of the large acidic EGFP
well reﬂects the subcellular localization of native PB1-F2.
3.2. The mitochondrial targeting sequence of PB1-F2
To map the MTS of PB1-F2, we generated a panel of
cDNAs encoding N- or C-terminal deletion mutants fused to
3xFLAG as a reporter on the N-terminal portion (Fig. 2)
and analyzed the immunoﬂuorescence distribution of each
deletion mutant (Fig. 1). A series of N-terminally deleted mu-
tants revealed that constructs expressing the PB1-F2 amino
acids 12–87, 22–87, 31–87, 39–87, 46–87, 51–87, 61–87, 62–
87 and 63–87 exhibited mitochondrial localization, whereas
constructs expressing the PB1-F2 amino acids 64–87, 65–87
and 69–87 exhibited diﬀuse cytoplasmic ﬂuorescence. These re-

















Fig. 2. A part of the chimeric 3xFLAG-PB1-F2 fusion constructs utilized in th
the left. Blue dots signify 3xFLAG. Green segments containing two red squar
(amino acids 63–75). All fusion proteins contain a linker residue (Leu) betwe
residues. The intracellular localization of the fusion proteins is summarizedwas between Ser63 and Leu64. On the other hand, a series of
C-terminally deleted mutants showed that constructs express-
ing the PB1-F2 amino acids 1–87, 1–76 and 1–75 exhibited
mitochondrial localization, whereas constructs expressing the
PB1-F2 amino acids 1–74, 1–73, 1–72, 1–71 and 1–63 exhibited
diﬀuse cytoplasmic ﬂuorescence. These results indicated the C-
terminal border of PB1-F2 MTS to be between Thr74 and
Arg75. We further analyzed the PB1-F2 MTS domain that is
necessary and suﬃcient for mitochondrial localization of its
fusion protein. Constructs expressing PB1-F2 amino acids
22–75, 31–75 and 46–75 (Fig. 1J–L) fused to 3xFLAG in the
N-terminal region localized in mitochondria, but 56–75 and
63–75 (Fig. 1M–O) had a cytoplasmic localization. These re-
sults suggest that the PB1-F2 residues in 46–75 are necessary
and suﬃcient MTS. To conﬁrm this ﬁnding, we expressed
PB1-F2 amino acids 46–75, 56–75 and 63–75 fused to EGFP
in the N-terminal region and further analyzed their localiza-
tion in transfected cells. EGFP-PB1-F2-46/75 localized in
mitochondria, but EGFP-PB1-F2-56/75 and -63/75 did not
(Fig. 1P–R). From these results, we concluded that the PB1-
F2 residues in 46–75 were necessary and suﬃcient for chimeric
proteins fused to the targeting element, and the PB1-F2 residue
strip 63–75 was a minimal requirement for mitochondrial




















is study. The residues incorporated in the fusion proteins are shown on
es (basic residues K73 and R75) represent the minimal MTS of PB1-F2
en 3xFLAG and the PB1-F2 sequence. ‘‘x’’ indicates the replaced basic
on the right as follows: M, mitochondrial; C, cytoplasmic.
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the eﬀect of a replacement of the basic residues with neutral
residues in the predicted PB1-F2 MTS. Replacement of Lys
and Arg residues in the C-terminal region at positions 73,
75, 78, 79 and 81 with Ala (K73A/R75A/K78A/R79A/R81A)
completely abolished mitochondrial localization of 3xFLAG-
PB1-F2, as reported previously [3]. However, replacement of
Lys and Arg residues with Ala at positions 78, 79 and 81
(K78A/R79A/R81/A) did not change the localization (Fig.
1S–U). However, replacement of Lys and Arg residues with
Ala at positions 73 and 75 in the predicted PB1-F2 MTS(K73A/R75A) completely abolished mitochondrial localiza-
tion (Fig. 1V–X). These results revealed that the two positively
charged residues at 73 and 75 in the predicted PB1-F2 MTS
were minimally required for mitochondrial targeting, but the
other positively charged residues in PB1-F2 were not essential.
3.3. Eﬀects of PB1-F2 expression on mitochondrial
morphology and function
It has been reported that the presence of PB1-F2 in the mito-
chondria of IAV-infected cells is associated with a loss of mito-
chondrial potential and mitochondrial rounding [2,3]. To
conﬁrm the functional similarity between the chimeric protein
and PB1-F2, we analyzed the mitochondrial morphology and
potential in cells expressing 3xFLAG-PB1-F2. As shown in
Fig. 3A–C, 11 ± 1.2% of 3xFLAG-PB1-F2-expressing cells
exhibited a change in the mitochondrial morphology with an
isolated and vesicular pattern, compared with non-expressing
cells with the normal interconnected and ﬁlamentous mito-
chondrial pattern. In contrast, expression of the fusion protein
of Discocoma sp. red ﬂuorescent protein and the mitochondrial
targeting sequence from the subunit VIII of human cytochrome
c oxidase did not modify mitochondrial morphology and typi-
cal ﬁlamentous mitochondria were observed (data not shown).
The results suggested that the change in the mitochondrial mor-
phology in 3xFLAG-PB1-F2 expressing cells was not an arti-
fact of the overexpression of a mitochondrial protein.
We also analyzed suppression of mitochondrial membrane
potential (MMP) of 3xFLAG-PB1-F2 expressing cells within
mitochondria by a decreased accumulation of MMP-sensitive
dye MitoTracker Red [22,23]. In the cells expressing
3xFLAG-PB1-F2 within mitochondria, 48 ± 2.8% of cells dis-
played a selective loss of mitochondrial MitoTracker Red
staining (Fig. 3D–F). However, the cells transfected with
3xFLAG-PB1-F2 mutants which do not localize in mitochon-
dria, such as 1/74 and 64/87, did not show a loss of MitoTrac-
ker Red staining (data not shown). We then analyzed the loss
of MMP by using other MMP-sensitive probes, such as
TMRE (Fig. 3G–I) and Rhodamine 123 (data not shown),
and the results obtained conﬁrmed the ﬁndings with MitoTrac-
ker Red staining. These results suggested that the 3xFLAG-
PB1-F2 expression in mitochondria induces a loss of MMP,
as reported for IAV-infected cells [2,3].Fig. 3. Eﬀects of PB1-F2 on transfected Vero cells. Vero cells
transfected with a plasmid expressing 3xFLAG-PB1-F2 were incubated
with MitoTracker Red (A–F) or with TMRE (G–I). Cells were ﬁxed,
permeabilized and analyzed by indirect immunoﬂuorescence with
mouse anti-FLAG monoclonal antibodies and FITC-conjugated anti-
mouse antibodies. (A–C) Fluorescent signals were analyzed with a LSM
510 confocal microscope. An arrow and multiple arrowheads indicate
the PB1-F2-expressing and not-expressing cells, respectively. (D-I)
Multiple arrows and a single arrowhead indicate the PB1-F2-expressing
cells with and without MitoTracker Red (D–F) or TMRE (G–I)
staining, respectively. (J–M) Vero cells infected with inﬂuenza virus
PR8 were incubated with annexin V conjugated with Alexa Fluor 594
(red) and ﬁxed 24 h after infection. Cells were permeabilized and
analyzed by indirect immunoﬂuorescence with mouse anti-cytochrome
c monoclonal antibodies and FITC-conjugated anti-mouse antibodies
(green) and Hoechst 33342 staining (blue). (N–V) Vero cells transfected
with plasmids expressing 3xFLAG-PB1-F2 were ﬁxed 24 h after
transfection. (N–P) 3xFLAG-PB1-F2 (green) and annexin V (red) were
stained. (Q–S) 3xFLAG-PB1-F2 (green) and nuclear DNA (blue)
were stained. (T–V) 3xFLAG-PB1-F2 (red) and cytochrome c (green)
were stained.
b
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lease of cytochrome c and apoptosis-inducing factors from
mitochondria is accompanied by a loss of MMP and mito-
chondrial swelling [23]. We analyzed whether the mere target-
ing of PB1-F2 to mitochondria is a suﬃcient apoptotic
trigger or not, in comparison with IAV-infected cells. As
shown in Fig. 3J–M, almost all Vero cells infected with
IAV exhibited the reported hallmarks of apoptosis [24], such
as phosphatidylserine exposure on the outer leaﬂet of the
plasma membrane detected by annexin V staining [25],
nuclear condensation by Hoechst 33342 staining and release
of cytochrome c from mitochondria into the cytosol. In these
experiments, we conﬁrmed IAV infection by using anti-inﬂu-
enza antibodies. In contrast to the IAV-infected cells, how-
ever, annexin V staining (Fig. 3N–P) and nuclear
condensation (Fig. 3Q–S) were little detected in the
3xFLAG-PB1-F2-expressing cells. In addition, cytochrome c
was predominantly detected in the mitochondria but not in
the cytosol in the 3xFLAG-PB1-F2-expressing cells (Fig.
3T–V). Similar results were obtained in transfected HeLa
and MDCK cells (data not shown). Taken together with
these results, the targeting of 3xFLAG-PB1-F2 to mitochon-
dria by itself might not be a suﬃcient factor for induction of
apoptosis.4. Discussion
Initiation of mitochondrial damages by IAV infection as
well as apoptosis is a principal pathogenicity of IAV infection
[2,11,12] and inﬂuenza associated encephalopathy [26]. We re-
port here the MTS of the newly identiﬁed virus protein PB1-F2
and its function in mitochondria. Gibbs et al. [3] have shown
that the amino acid residues of PB1-F2 69–82 are the minimal
MTS by analyzing intracellular localization of the chimeric
PB1-F2 protein fused to a relatively large molecular mass of
29 kDa EGFP at the C-terminus. In our follow-up experiments
of the MTS, we found that eﬃciency of mitochondrial target-
ing of the chimeric PB1-F2-EGFP was low at 14 ± 1.5% in
comparison with the eﬃciency of PB1-F2 at about 70% of
PB1-F2-positive cells after infection of HeLa cells with inﬂu-
enza virus PR8. To bring the targeting eﬃciency of the chime-
ric PB1-F2 protein close to the native one, we made chimeric
protein consisting of PB1-F2 fused to a small 2.9 kDa reporter
protein 3xFLAG instead of EGFP and then analyzed the eﬃ-
ciency of mitochondrial targeting. In our assay conditions, we
achieved mitochondrial localization of the 3xFLAG-PB1-F2 at
75 ± 4% in the PB1-F2-positive cells (Fig. 1D–F) being similar
to the rate of native PB1-F2 (Fig. 1A–C). Analysis of the N-
and C-terminal deletion mutants of PB1-F2 fused to a
3xFLAG at the N-terminus showed that the residues 46–75
were necessary and suﬃcient, and the residues 63–75 and both
Lys73 and Arg75 were minimal requirements for mitochon-
drial localization (Figs. 1 and 2). Although the mapped mini-
mal essential MTS determined by PB1-F2-EGFP as reported
[3] and by 3xFLAG-PB1-F2 in our experiments were over-
lapped in the residues 69–75, the diﬀerence of the MTS be-
tween them might be due to the steric hindrance of chimeric
PB1-F2 by the molecular size of reporter protein and/or the
positions of tags at the N- or C-terminus for fusion. It has been
well known that positively charged amphipathic helices arecommonly used to target cellular proteins to mitochondria
[27] and PB1-F2 has predicted a-helical regions between amino
acids 54–62 and 73–82 [3]. These ﬁndings suggested that, in
addition to the minimal essential MTS of the residues 63–75,
a-helical region of the residues 54–62 may be important for
suﬃcient mitochondrial localization of PB1-F2. The expres-
sion of PB1-F2 resulted in speciﬁc alterations in mitochondrial
morphology and distribution (Fig. 3A–C). It is established that
the mitochondria are highly dynamic organelles that are typi-
cally organized in the form of a continuous reticulum, but can
be fragmented into smaller, tubular structures depending on
the cell stage. The mitochondrion is fragmented during the S
phase, but the organelle is organized as a reticulum in the
G1 phase [28]. It has recently been shown that human T cell
leukemia virus type 1 (HTLV-1) p13, the preceding viral pro-
tein that induces a morphological change of mitochondria into
round-shaped clusters, suppresses tumor growth and cell pro-
liferation [29,30]. Thus, it may be hypothesized that PB1-F2 af-
fects the cell cycle and detains it at the S phase. Furthermore,
about one half of the mitochondrial PB1-F2-expressing cells
showed a decrease in the staining with MitoTracker Red
(Fig. 3D–F), TMRE (Fig. 3G–I) and Rhodamine 123 (data
not shown), suggesting a loss of MMP as a result of depolar-
ization of the transmembrane potential. It has been reported
that the opening of high conductance permeability transition
pores in the mitochondrial inner membrane initiates the mito-
chondrial permeability transition and the loss of MMP, lead-
ing to mitochondrial depolarization, and an uncoupling of
oxidative phosphorylation, which in turn leads to ATP deple-
tion and apoptosis [31,32]. However, we could not detect any
signiﬁcant apoptotic signals by annexin V staining (Fig. 3N–
P), Hoechst 33342 staining (Fig. 3Q–S), the release of cyto-
chrome c from mitochondria (Fig. 3T–V) and DNA-laddering
(data not shown) in PB1-F2-expressing Vero, HeLa and
MDCK cells, although apparent apoptosis along with a loss
of MMP in these cells was detected by infection of inﬂuenza
virus. Gibbs et al. [3] have previously reported that the expres-
sion of PB1-F2-65/87-EGFP in transfected HeLa cells sup-
presses the MMP, but PB1-F2-1/87-EGFP does not,
although the mechanisms of the diﬀerence in the eﬀects be-
tween them have not been clariﬁed. In addition to these ﬁnd-
ings, our data proposed a hypothesis that PB1-F2 expression
alone is not suﬃcient for the initiation of apoptosis. In con-
trast, Chanturiya et al. [33] have recently shown that PB1-F2
creates variably sized pores in planar lipid membranes and
may induce the permeabilization and destabilization of
mitochondrial membranes. Further studies on the mecha-
nisms of PB1-F2 in mitochondrial damage are now under
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